1
|
Cooper CS, Park M, Blair DG, et al:
Molecular cloning of a new transforming gene from a chemically
transformed human cell line. Nature. 311:29–33. 1984. View Article : Google Scholar : PubMed/NCBI
|
2
|
Knudsen BS and Edlund M: Prostate cancer
and the met hepatocyte growth factor receptor. Adv Cancer Res.
91:31–67. 2004. View Article : Google Scholar : PubMed/NCBI
|
3
|
Peruzzi B and Bottaro DP: Targeting the
c-Met signaling pathway in cancer. Clin Cancer Res. 12:3657–3660.
2006. View Article : Google Scholar : PubMed/NCBI
|
4
|
Kong DS, Song SY, Kim DH, et al:
Prognostic significance of c-Met expression in glioblastomas.
Cancer. 115:140–148. 2009. View Article : Google Scholar : PubMed/NCBI
|
5
|
Lee YJ, Kim DH, Lee SH, Kim DW, Nam HS and
Cho MK: Expression of the c-Met proteins in palignant skin cancers.
Ann Dermatol. 23:33–38. 2011. View Article : Google Scholar : PubMed/NCBI
|
6
|
De Oliveira AT, Matos D, Logullo AF, et
al: MET Is highly expressed in advanced stages of colorectal cancer
and indicates worse prognosis and mortality. Anticancer Res.
29:4807–4811. 2009.PubMed/NCBI
|
7
|
Matteucci E, Bendinelli P and Desiderio
MA: Nuclear localization of active HGF receptor Met in aggressive
MDA-MB231 breast carcinoma cells. Carcinogenesis. 30:937–945. 2009.
View Article : Google Scholar : PubMed/NCBI
|
8
|
Ichimura E, Maeshima A, Nakajima T and
Nakamura T: Expression of c-met/HGF receptor in human non-small
cell lung carcinomas in vitro and in vivo and its prognostic
significance. Jpn J Cancer Res. 87:1063–1069. 1996. View Article : Google Scholar : PubMed/NCBI
|
9
|
Kuniyasu H, Yasui W, Yokozaki H, Kitadai Y
and Tahara E: Aberrant expression of c-met mRNA in human gastric
carcinomas. Int J Cancer. 55:72–75. 1993. View Article : Google Scholar : PubMed/NCBI
|
10
|
Belfiore A, Gangemi P, Costantino A, et
al: Negative/low expression of the Met/hepatocyte growth factor
receptor identifies papillary thyroid carcinomas with high risk of
distant metastases. J Clin Endocrinol Metab. 82:2322–2328.
1997.PubMed/NCBI
|
11
|
Humphrey PA, Zhu X, Zarnegar R, et al:
Hepatocyte growth factor and its receptor (c-MET) in prostatic
carcinoma. Am J Pathol. 147:386–396. 1995.PubMed/NCBI
|
12
|
Birchmeier C, Birchmeier W, Gherardi E and
Vande Woude GF: Met, metastasis, motility and more. Nat Rev Mol
Cell Biol. 4:915–925. 2003. View
Article : Google Scholar : PubMed/NCBI
|
13
|
Knudsen BS, Gmyrek GA, Inra J, et al: High
expression of the Met receptor in prostate cancer metastasis to
bone. Urology. 60:1113–1117. 2002. View Article : Google Scholar : PubMed/NCBI
|
14
|
Watanabe M, Fukutome K, Kato H, et al:
Progression-linked overexpression of c-Met in prostatic
intraepithelial neoplasia and latent as well as clinical prostate
cancers. Cancer Lett. 141:173–178. 1999. View Article : Google Scholar
|
15
|
Pisters LL, Troncoso P, Zhau HE, Li W, von
Eschenbach AC and Chung LW: c-met proto-oncogene expression in
benign and malignant human prostate tissues. J Urol. 154:293–298.
1995. View Article : Google Scholar : PubMed/NCBI
|
16
|
Tu WH, Zhu C, Clark C, Christensen JG and
Sun Z: Efficacy of c-Met inhibitor for advanced prostate cancer.
BMC Cancer. 10:5562010. View Article : Google Scholar : PubMed/NCBI
|
17
|
Varkaris A, Corn PG, Gaur S, Dayyani F,
Logothetis CJ and Gallick GE: The role of HGF/c-Met signaling in
prostate cancer progression and c-Met inhibitors in clinical
trials. Expert Opin Investig Drugs. 20:1677–1684. 2011. View Article : Google Scholar : PubMed/NCBI
|
18
|
Gross ME, Jo S and Agus DB: Update on
HER-kinase-directed therapy in prostate cancer. Clin Adv Hematol
Oncol. 2:53–56. 642004.PubMed/NCBI
|
19
|
Erbersdobler A, Fritz H, Schnöger S, et
al: Tumour grade, proliferation, apoptosis, microvessel density,
p53, and bcl-2 in prostate cancers: differences between tumours
located in the transition zone and in the peripheral zone. Eur
Urol. 41:40–46. 2002. View Article : Google Scholar
|
20
|
Bubendorf L: High-throughput microarray
technologies: from genomics to clinics. Eur Urol. 40:231–238. 2001.
View Article : Google Scholar : PubMed/NCBI
|
21
|
Miyamoto M, Ojima H, Iwasaki M, et al:
Prognostic significance of overexpression of c-Met oncoprotein in
cholangiocarcinoma. Br J Cancer. 105:131–138. 2011. View Article : Google Scholar : PubMed/NCBI
|
22
|
Amemiya H, Menolascino F and Peña A: Role
of the expression of c-Met receptor in the progression of gastric
cancer. Invest Clin. 51:369–380. 2010.(In Spanish).
|
23
|
Freudlsperger C, Alexander D, Reinert S
and Hoffmann J: Prognostic value of c-Met expression in oral
squamous cell carcinoma. Exp Ther Med. 1:69–72. 2010.PubMed/NCBI
|
24
|
Previdi S, Abbadessa G, Dalò F, France DS
and Broggini M: Breast cancer-derived bone metastasis can be
effectively reduced through specific c-MET inhibitor tivantinib
(ARQ 197) and shRNA c-MET knockdown. Mol Cancer Ther. 11:214–223.
2012. View Article : Google Scholar : PubMed/NCBI
|
25
|
Liu X, Wang Q, Yang G, et al: A novel
kinase inhibitor, INCB28060, blocks c-MET-dependent signaling,
neoplastic activities, and cross-talk with EGFR and HER-3. Clin
Cancer Res. 17:7127–7138. 2011. View Article : Google Scholar : PubMed/NCBI
|